Current Report Filing (8-k)
August 11 2021 - 12:19PM
Edgar (US Regulatory)
0001697884
false
tru
0001697884
2020-08-07
2020-08-07
0001697884
2021-08-07
2021-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August 7, 2020
VITASPRING BIOMEDICAL CO. LTD.
(Exact Name of Registrant as Specified in Charter)
|
NV
|
|
333-216465
|
|
37-1836726
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
400 Spectrum Center Dr. 1620
Irvine, CA 92618
|
(Address of Principal Executive Offices)
(Zip Code)
|
(949)2029235
(Registrant's telephone number, including
area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
____________________________________________________________________________________
Item 5.02 Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers.
Effective August 7, 2020, Chu Pao-Chi Chairman of the Board of Directors,
and Chief Executive Officer of the Company, resigned his position as CEO and current secretary of the Company, Kao Cheng-Hsiang, was appointed
CEO and retains his position as Secretary.
The remaining officers of the Company, Lin Jer-Li Chief Technical Officer
of the Company and Chen Yen Xun Technical Vice-President of the Company, remain the same.
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
VITASPRING BIOMEDICAL CO. LTD.
|
|
August 11, 2021
|
|
By: /s/ Kao Cheng-Hsiang
Kao Cheng-Hsiang
Chief Executive Officer
|
VitaSpring Biomedical (CE) (USOTC:VSBC)
Historical Stock Chart
From Oct 2024 to Nov 2024
VitaSpring Biomedical (CE) (USOTC:VSBC)
Historical Stock Chart
From Nov 2023 to Nov 2024
Real-Time news about VitaSpring Biomedical Company Ltd (CE) (OTCMarkets): 0 recent articles
More Vitaspring Biomedical Co. Ltd. News Articles